

DPHHS HAN

Information Sheet



DATE

August 12, 2026

SUBJECT

Risk of Severe Arboviral Disease in Patients Receiving B Cell-Depleting or Modulating Medications

CDC HAN SUMMARY

The Centers for Disease Control and Prevention (CDC) has issued a Health Advisory to share information and notify clinicians, public health authorities, and the public about the risk of severe arboviral neuroinvasive disease among patients who are receiving B-cell-depleting or B-cell-modulating medications, particularly anti-CD20 monoclonal antibodies (mAbs). Patients and their providers should be aware of this risk to help patients protect themselves against mosquito and tick bites, which can increase their risk of arboviral disease.

BACKGROUND

See CDC HAN 00532.

INFORMATION

See CDC HAN 00532.

RECOMMENDATIONS

See CDC HAN 00532.

CDC HAN FULL REPORT

Please use the following link to access the full CDC HAN:

- <https://www.cdc.gov/han/php/notices/han00532.html>